Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 26 27 28 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Mologen–Global Derivative Trading: credit, 201609– convertible bond with total nominal value of €2.54m by largest investor GDT 2016-09-26
Evotec–France (govt): cancer drug discovery, 201609– research collab with Inserm in translational oncology 2016-09-22
iOmx Therapeutics–Akampion: public relations, 201609 service existent by Akampion 2016-09-22
iOmx Therapeutics–SEVERAL: investment, 201609 financing round Series A €40m co-led by MPM Capital + Sofinnova Partners 2016-09-22
Lipotype–Germany (govt): grant, 201609 support for Skin Lipidomics developm from Central Innovation Programme for SMEs 2016-09-22
Scienion–Berlin (govt): investment, 201609 DIVESTMENT IBB Beteiligungsgesellschaft sells its shareholding in Scienion AG 2016-09-22
Artios Pharma–SEVERAL: investment, 201609 financing round Series A £25m led by SV Life Sciences 2016-09-21
Bayer–Evotec: drug discovery services, 201609– collab 5y €14m minimum + €300m milestones + royalties multi-target research for kidney diseases 2016-09-21
Roche–BioNTech: mRNA technology, 201609– collab ww $310m upfront + near-term milestones + cost-profit-sharing developm mRNA cancer therapies Genentech 2016-09-21
Organobalance–Novo Group: investment, 201609 acquisition €na of Organobalance GmbH by Novozymes 2016-09-15
AC Immune–SEVERAL: investment, 201609 US IPO $66m net $57.8m net with 6m common shares at $11/share at Nasdaq 2016-09-13
Mologen–SEVERAL: investment, 201609–201610 capital increase €13.6m 11.316m common shares at €1.2/share (raising no. of existing shares by up to 50%) 2016-09-13
PaxVax–Leukocare: drug formulation technology, 201609– license to SPS technology for one live viral vaccine product of PaxVax 2016-09-13
TATAA Biocenter–Basepair: bioinformatics, 201609– collab TATAA to offer Basepair’s data analysis s/w for NGS 2016-09-13
Inflazome–Fountain Healthcare Partners: investment, 201609 financing round Series A totalling $17m incl founding investor FHP 2016-09-12
Inflazome–Novartis: investment, 201609 financing round Series A totalling $17m incl founding investor Novartis Venture Fund 2016-09-12
Inflazome–SEVERAL: investment, 201609 financing round Series A $17m from Novartis Venture Fund + Fountain Healthcare Partners 2016-09-12
Lonza–Harvard Univ: AAV vectors, 201609– license to use Anc-AAV technology from Massachusetts Eye and Ear 2016-09-12
CRISPR Therapeutics–SEVERAL: investment, 201609–201610 US IPO $56m+$8.4m with 4m+600k shares at $14/share at Nasdaq Global Market 2016-09-09
Bayer–Helmholtz: plant science, 201609– collab strategic research 5y phenotyping for products by Bayer CropScience + FZJ 2016-09-08
Vivasure Medical–SEVERAL: investment, 201609 financing round Series C €16.2m led by LSP Health Economics Fund + co-led by Evonik VC 2016-09-08
Curetis–Siemens: GEAR database, 201609 acquisition €na of ww rights to GEAR database + related IP + know-how by Curetis from STA 2016-09-07
Oncovision–Bruker: investment, 201609 acquisition €na of preclinical imaging business of Oncovision by Bruker 2016-09-07
Pure Communications–W2O Group: investment, 201609 acquisition €na of Pure Communications by W2O Group 2016-09-07
Biomeva–Asahi Glass: investment, 201609 acquisition 100% of Biomeva GmbH by Asahi Glass 2016-09-06
Rigontec–Boehringer: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor BIVF 2016-09-06
Rigontec–Forbion: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Forbion Capital Partners 2016-09-06
Rigontec–High-Tech Gründerfonds: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor HTGF 2016-09-06
Rigontec–MacDougall Biomedical Communications: public relations, 201609 service existent by MacDougall 2016-09-06
Rigontec–Mitsubishi Chemical: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor MP Healthcare 2016-09-06
Rigontec–North Rhine-Westphalia (govt): investment, 201609 financing round Series A 3rd + final closing totalling €15m w returning investor NRW.BANK 2016-09-06
Rigontec–SEVERAL: investment, 201609 financing round Series A 3rd + final closing €15m from existing investors 2016-09-06
Rigontec–Sunstone Capital: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Sunstone Capital 2016-09-06
Rigontec–Wellington Partners: investment, 201609 financing round Series A 3rd + final closing totalling €15m incl returning investor Wellington 2016-09-06
IBI-Lorenzini–Celonic: cell line development, 201609– collab using CHOvolution to establish cell lines for RnD 2016-09-05
Unigeo Agricultura de Precisâo–SGS: investment, 201609 acquisition of 75% stake by SGS 2016-09-02
DiViNe project–Affilogic: vaccine purification technology, 201609 collab Affilogic is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Aquaporin: vaccine purification technology, 201609 collab Aquaporin is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–EU (govt): grant, 201609c– Horizon 2020 grant 5y to advance vaccine purification led by iBET 2016-09-01
DiViNe project–GSK: vaccine purification technology, 201609 collab GSK Italy is partner in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–iBET (PT): vaccine purification technology, 201609 collab GenIbet + iBET are partners in Horizon 2020 project led by iBET 2016-09-01
DiViNe project–Merck (DE): vaccine purification technology, 201609– collab Merck is partner in Horizon 2020 project led by iBET 2016-09-01
Innovative Medicines Initiative–Lipotype: lipidomics, 201609– collab Lipotype is participant in RHAPSODY project on type 2 diabetes 2016-09-01
Phagenesis–Nestlé: investment, 201609– acquisition €na staged + milestone-based by Nestlé Health Science 2016-09-01
Rigontec–Germany (govt): business development, 201609– supply service support in US with German Accelerator Life Sciences programme 2016-09-01
Roche–Horizon Discovery: reference standards, 201609– collab developm + commercialisation of IHC Reference Standards with Ventana 2016-09-01
Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver 2016-09-01
SPEware–Tecan: investment, 201608–201609 acquisition of SPEware for $50m in cash + $10m milestones 2016-08-31
Boehringer–Saniona: schizophrenia drugs, 201608– collab reserach €5m upfront + €85m milestones + royalties to identify compounds for schizophrenia 2016-08-29
Cyprotex–Danaher: mass spectrometer, 201608 supply two AB Sciex TripleTOF 6600 systems, one with Eksigent MicroLC + IonDrive + SWATH 2016-08-25
Cyprotex–Waters: mass spectrometer, 201608 supply existent of Xevo G2-XS QTof MS system used for mass metabolite identification studies 2016-08-25
Denali Therapeutics–F-Star: antibody technology, 201608– collab r+d bispecific antibodies for drug delivery across blood-brain barrier 2016-08-25
Earlybird–SEVERAL: investment, 201608 first closing of Earlybird Health Tech Fund incl investors NRW.Bank + Generali + Miele + BMWE + Barmer GEK 2016-08-24
Ayoxxa–Märzhäuser: microplate reader, 201608 collab developm + contract manufacturing of Ayoxxa Reader AR01 by Märzhäuser 2016-08-22
InterHealth Nutraceuticals–Lonza: investment, 201608–201609 acquisition of InterHealth for up to $300m in upfront + earn-out from Kainos Capital 2016-08-15
Mologen–NN: business development services, 201608c– supply service to find outlicensing opportunities for lefitolimod 2016-08-11
Oculis–SEVERAL: investment, 201608 financing round Series A led by Brunnur Ventures + Silfurberg 2016-08-11
Thermo Fisher–Hamilton: liquid handling products, 201608– direct non-excl distribution of automation products for forensics in EMEA + China 2016-08-11
Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics 2016-08-11
Gilead–Polyphor: drug discovery, 201608– collab + license agreem identifying + optimise drug candidates using macrocycle platform 2016-08-10
Akvolution–High-Tech Gründerfonds: investment, 201608 financing round Series A incl returning investor HTGF 2016-08-04
Akvolution–SEVERAL: investment, 201608 financing round Series A from HTGF + VNG Innovation + Bamag + private investors 2016-08-04
Oncgnostics–SEVERAL: investment, 201608–201606 crowdfunding campaign €500k via Seedmatch platform 2016-08-04
Arcus Biosciences–SEVERAL: investment, 201608 2nd financing round $70m led by new investor GV plus new + all existing investors 2016-08-01
ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m 2016-08-01
Applied Micorarrays–Scienion: print/spotting technology, 201607– collab strategic partnership to support developm + production of IVD products 2016-07-28
Merck (DE)–Amoy Diagnostics: molecular diagnostics, 201607– collab developm liquid biopsy RAS biomarker CRC test based on ADx-SuperARMS for China 2016-07-28
Eurofins–Lablicate: mass spectrometry software, 201607 supply existent Eurofins is reference customer for OpenChrom s/w 2016-07-27
Symrise–Lablicate: mass spectrometry software, 201607 supply existent Symrise is reference customer for OpenChrom s/w 2016-07-27
Lophius–SEVERAL: investment, 201607 financing round €4.25m led by VRD GmbH + incl Bayern Kapital + Wolf Biotech + WIC GmbH 2016-07-26
Numares–Bavaria (govt): investment, 201607 financing round incl €2m from Wachstumsfonds Bayern managed by Bayern Kapital 2016-07-26
Numares–SEVERAL: investment, 201607 financing round incl €2m from Wachstumsfonds Bayern managed by Bayern Kapital 2016-07-26
InflaRx–SEVERAL: investment, 201607 financing round Series C €31m incl new investor Staidson Hongkong Investment Co Ltd 2016-07-21
Molecular Health–Akampion: public relations, 201607 service existent EMEA media + investor relations by Akampion 2016-07-21
Relypsa–Galenica: investment, 201607–201609 acquisition $1.53b cash tender offer $32/share 2016-07-21
Jounce Therapeutics–Nextech: investment, 201607 existent investment of Nextech Oncology Fund IV 2016-07-20
Kura Oncology–Nextech: investment, 201607 existent investment of Nextech Oncology Fund IV 2016-07-20
Nextech–SEVERAL: investment, 201607 final closing of $64m Oncology Fund IV with Limited Partners in US + Europe + Asia 2016-07-20
Peloton Therapeutics–Nextech: investment, 201607 existent investment of Nextech Oncology Fund IV 2016-07-20
ViroCyt–Sartorius: investment, 201607 acquisition valueing ViroCyt at $16m 2016-07-15
Boehringer–Univ Dundee: PROTAC technology, 201607– collab developm of PROTACs 2016-07-14
Pro Farma–Recordati: investment, 201607 acquisition CHF16m 100% of Pro Farma AG by Recordati 2016-07-14
RedoxTherapies–Juno Therapeutics: investment, 201607 acquisition $10m cash + milestones of RedoxTherapies by Juno 2016-07-14
Bayer–X-Chem: small-molecule drug discovery, 2016– collab extension of access to DEX technology up to $528m in upfront + r+d funding + milestones 2016-07-12
Delenex–Cell Medica: investment, 201607 acquisition €na of Delenex Pharmaceuticals AG by Cell Medica 2016-07-12
Valneva–EU (govt): credit, 201607 EIB RnD loan up to €25m in tranches within 24-months period to advance vaccine programs 2016-07-12
AMSilk–Kirchhoff Consult: public relations, 201607 service existent by Kirchhoff Consult AG 2016-07-11
AMSilk–SEVERAL: investment, 201607 financing round with existing investors MIG Fonds + AT Newtec 2016-07-11
Antibiotic Research UK–Evotec: drug discovery services, 201607– collab research €na to discovery antibiotic resistance breakers (ARBs) 2016-07-11
GenePOC–Debiopharm: investment, 201607 acquisition of majority share by acquiring all shares from Emerillon Capital + others 2016-07-11
Thomson Reuters–Onex Corp: investment, 201607–201610 acquisition $3.55b in cash of Thomson Reuters IP + Science business by Onex + Baring PE Asia 2016-07-11
CryoTherapeutics–Creathor Ventures: investment, 201607 financing round Series B totalling €5.2m incl lead investor Creathor Venture 2016-07-07
CryoTherapeutics–Germany (govt): investment, 201607 financing round Series B totalling €5.2m incl returning co-investor KfW 2016-07-07
CryoTherapeutics–Getz Brothers: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor Getz Brothers 2016-07-07
CryoTherapeutics–High-Tech Gründerfonds: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor HTGF 2016-07-07
CryoTherapeutics–North Rhine-Westphalia (govt): investment, 201607 financing round Series B totalling €5.2m incl returning co-investor NRW.Bank 2016-07-07
CryoTherapeutics–Peppermint: investment, 201607 financing round Series B totalling €5.2m incl returning co-investor Peppermint CBF 2016-07-07
CryoTherapeutics–SEVERAL: investment, 201607 financing round Series B €5.2m led by Creathor incl NRW.Bank + Peppermint CBF + HTGF et al 2016-07-07
Evotec–MIT: CRISPR technology, 201607– research tool license non-excl to CRISPR-Cas9 gene editing technology from Broad Institute 2016-07-06
kSep Systems–Sartorius: investment, 201607 acquisition $28m of kSep Holdings Inc by SSB 2016-07-06
next pagenext page 1 2 3 ... 26 27 28 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px

» top